[go: up one dir, main page]

ITMI20022511A1 - USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION. - Google Patents

USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.

Info

Publication number
ITMI20022511A1
ITMI20022511A1 IT002511A ITMI20022511A ITMI20022511A1 IT MI20022511 A1 ITMI20022511 A1 IT MI20022511A1 IT 002511 A IT002511 A IT 002511A IT MI20022511 A ITMI20022511 A IT MI20022511A IT MI20022511 A1 ITMI20022511 A1 IT MI20022511A1
Authority
IT
Italy
Prior art keywords
omega
pharmaceutical compositions
order
compositions containing
atrial fibrillation
Prior art date
Application number
IT002511A
Other languages
Italian (it)
Inventor
Jadranka Rogan
Original Assignee
Victorix Assets Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victorix Assets Ltd filed Critical Victorix Assets Ltd
Priority to IT002511A priority Critical patent/ITMI20022511A1/en
Priority to PCT/EP2003/013125 priority patent/WO2004047835A1/en
Priority to EP03767610A priority patent/EP1565177A1/en
Priority to AU2003292080A priority patent/AU2003292080A1/en
Publication of ITMI20022511A1 publication Critical patent/ITMI20022511A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT002511A 2002-11-26 2002-11-26 USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION. ITMI20022511A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IT002511A ITMI20022511A1 (en) 2002-11-26 2002-11-26 USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.
PCT/EP2003/013125 WO2004047835A1 (en) 2002-11-26 2003-11-21 Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids to prevent atrial fibrillation
EP03767610A EP1565177A1 (en) 2002-11-26 2003-11-21 Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids to prevent atrial fibrillation
AU2003292080A AU2003292080A1 (en) 2002-11-26 2003-11-21 Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids to prevent atrial fibrillation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002511A ITMI20022511A1 (en) 2002-11-26 2002-11-26 USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.

Publications (1)

Publication Number Publication Date
ITMI20022511A1 true ITMI20022511A1 (en) 2004-05-27

Family

ID=32375543

Family Applications (1)

Application Number Title Priority Date Filing Date
IT002511A ITMI20022511A1 (en) 2002-11-26 2002-11-26 USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.

Country Status (4)

Country Link
EP (1) EP1565177A1 (en)
AU (1) AU2003292080A1 (en)
IT (1) ITMI20022511A1 (en)
WO (1) WO2004047835A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
FR2902659A1 (en) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa DHA ESTER AND ITS USE IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
WO2008066745A1 (en) * 2006-11-22 2008-06-05 Reliant Pharmaceuticals, Inc. Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids
RU2362553C1 (en) * 2007-12-10 2009-07-27 Федеральное государственное учреждение "Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова Федерального агентства по высокотехнологичной медицинской помощи" Way of prevention of auricles fibrillation after operation of coronary shunting at patients with ischemic heart disease
BRPI1009431A2 (en) 2009-03-09 2016-03-01 Pronova Biopharma Norge As pharmaceutical and food supplement concentrates, drug delivery systems, method of treating at least one health problem in subject in need thereof and method and system
EP3563842A1 (en) * 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2424356B1 (en) * 2009-04-29 2017-08-23 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
EP3698781A1 (en) 2009-06-15 2020-08-26 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid for treating myocardial infarction in a subject on concomitant statin therapy
US20110082205A1 (en) * 2009-10-01 2011-04-07 Panker Cynthia A Docosahexaenoic Acid Gel Caps
FR2963790B1 (en) 2010-08-11 2012-09-28 Pf Medicament PANTHENYL DOCOSAHEXAENEOATE AND USE THEREOF IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
KR20240135078A (en) 2018-09-24 2024-09-10 애머린 파마슈티칼스 아일랜드 리미티드 Methods of reducing the risk of cardiovascular events in a subject
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1308613B1 (en) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS.
EP1157692B1 (en) * 2000-05-22 2005-10-05 Pro Aparts - Investimentos E Consultoria Lda Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
ITMI20010129A1 (en) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE THERAPY OF HEART INSUFFICIENCY AND HEART FAILURE
ITMI20020269A1 (en) * 2002-02-12 2003-08-12 Victorix Assets Ltd USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY

Also Published As

Publication number Publication date
WO2004047835A1 (en) 2004-06-10
EP1565177A1 (en) 2005-08-24
AU2003292080A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
ITMI20020269A1 (en) USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL STERES IN PATIENTS WITH HEART INSUFFICIENCY
GB2409644B (en) Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
HUP0303817A3 (en) Medium-chain length fatty acids, glycerides and analogues as neutrophile survival and activation factors and pharmaceutical compositions containing them
ITMI20022511A1 (en) USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING ETHYL ESTERS OF OMEGA-3 POLYUNSATURATED ACIDS IN THE ORDER OF ATRIAL FIBRILLATION.
HUP0303347A3 (en) Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis polymorphonucleate and mononucleate cells, process for their preparation and pharmaceutical compositions containing them
AU2003208920A1 (en) Fatty acid-containing compositions and methods for the treatment of cytokine mediated disorders
AU2003217759A1 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
EE200300297A (en) Use of essential fatty acid containing a mixture of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester
EE200200666A (en) Process for the preparation of cyclopropylcarboxylic acid esters and derivatives
ITMI20022627A1 (en) USE OF A MIXTURE OF FATTY ACID ESTERS AS A FUEL
AU2003223930A1 (en) Pharmaceutical use of boronic acids and esters thereof
FI20022129A7 (en) Fatty acid composition, its preparation and use
BRPI0606445A2 (en) mucin hypersecretion inhibitors and methods of use
AU2614200A (en) Composition for stabilizing and potentiating the action of anti-angiogenic substances by polyunsaturated fatty acids
AU2003222083A1 (en) Acid and ester compounds and methods of using the same
EP1617830A4 (en) Esterified fatty acid composition
ITMI20011762A0 (en) 17ALPHA,21-DIHYDROXYPREGENE ESTERS, THEIR USE AS ANTI-ANDROGENETIC AGENTS AND PROCEDURES FOR THEIR PREPARATION
ZA200502613B (en) Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
AU2003280387A1 (en) Pharmaceutical formulation comprising azithrocycin monohydrate
IT1292126B1 (en) WAX ESTERS ENRICHED IN UNSATURATED OMEGA-3 FATTY ACIDS, THEIR PREPARATION AND USE
ITMI20020115A1 (en) USE OF OMEGA-3 POLYUNSATURATED ACID ETHYL ESTERS IN CARDIAC SUFFICIENCY OPTIENTS
AU2003263480A1 (en) Oral pharmaceutical compositions of fenofibrate having high bioavailability
HK1084865A (en) Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids to prevent atrial fibrillation
AU2003245899A1 (en) Cosmetic and/or pharmaceutical preparations comprising retinol esters
AU2003228263A1 (en) THE EFFERVESCENT PHARMACEUTICAL DOSAGE FORM OF ESTERS AND ESTER SALTS OF 6 Alpha METHYLPREDNISOLONE SUCCINATE, PROCEDURE FOR ITS OBTAINING AND APPLICATION